NAME: Soriano-Sarabia, Natalia. era COMMONS USER NAME: natalia_soriano

Similar documents
Induction and Clearance of Latent HIV Infection:

Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome

Immunodeficiency. (2 of 2)

Treatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain

cure research HIV & AIDS

The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco

Professor Jonathan Weber

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure

Forward Looking Statements

Immunity and Infection. Chapter 17

Human Immunodeficiency Virus

PART VI! IMPLICATIONS FOR THERAPIES

GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW

Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies

Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir

HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the

When to start: guidelines comparison

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

Approaching a Cure Daniel R. Kuritzkes, MD

Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin

5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1

Appendix B Biographical Sketch example

HCV RNA in peripheral blood cell subsets in HCV HIV coinfected patients at the end of PegIFN RBV treatment is associated with virologic relapse

HIV 101: Fundamentals of HIV Infection

In Search of a Salient Marker of Immune Function for Population Health Research

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

1. Overview of Adaptive Immunity

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

JCM (Revised version, June 23 th 2011)

Inves)gación básica y curación del VIH- 1

Institut Pasteur du Cambodge scientific report and 2018 prospects Rapport 2017 et programmation scientifique 2018 IMMUNOLOGY PLATFORM

T-Pharmacytes for the Targeted Eradication of HIV Reservoirs

Chapter 10 (pages ): Differentiation and Functions of CD4+ Effector T Cells Prepared by Kristen Dazy, MD, Scripps Clinic Medical Group

the Office of Research Application Portal: Materials to submit:

GESIDA 2018 ANTIRETROVIRAL TREATMENT MAINTENANCE STRATEGIES AND BLOOD TELOMERE LENGTH CHANGE

227 28, 2010 MIDTERM EXAMINATION KEY

Pathogenesis Update Robert F. Siliciano, MD, PhD

Biology of Immune Aging

CROI 2016 Review: Immunology and Vaccines

HIV / AIDS Pathogenesis 2

BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

MID-TERM EXAMINATION

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018

Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.

The Innate Immune Response

HIV disease progression is associated with exhaustion of lymphopoiesis driven by immune activation

Vicente Soriano Department of Infectious Diseases

Can HPV, cervical neoplasia or. HIV transmission?

BIOGRAPHICAL SKETCH INSTITUTION AND LOCATION DEGREE YY FIELD OF STUDY. Biological Science

General information. Cell mediated immunity. 455 LSA, Tuesday 11 to noon. Anytime after class.

PART II! IMMUNE SENESCENCE!

T Memory Stem Cells: A Long-term Reservoir for HIV-1

Professor Vincent Soriano

NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 September 01.

IAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal

Daniel J Escudero, PhD

coinfected patients predicts HBsAg clearance during long term exposure to tenofovir

DEGREE (if applicable) NOTE: The Biographical Sketch may not exceed five pages. Follow the formats and instructions below.

HIV AND INFLAMMATION: A NEW THREAT

Higher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

HIV Immunopathogenesis. Modeling the Immune System May 2, 2007

1. PICO question. Interventions Reference standard or comparators Outcomes. Study design Other

Predictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg

Targeting latent HIV infection: on the road towards an HIV Cure

Pediatric HIV Cure Research

Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF

TRANS-NIH PLAN FOR HIV RELATED RESEARCH

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline

CFAR Supplement Announcement in HIV/AIDS FY2014

Adaptive Immunity. Lecture 14 Biology W3310/4310 Virology Spring Life is simple, but we insist on making it complicated CONFUCIUS

How to best manage HIV patient?

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART

Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles

Immunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T

Innovative diagnostics for HIV, HBV and HCV

Module R: Recording the HIV Reservoir

Early Antiretroviral Therapy

Section Lectures: Immunology/Virology Time: 9:00 am 10:00 am LRC 105 A & B

HIV-DNA: nuovo marcatore virologico. Metodiche a confronto per la quantificazione di HIV-DNA

HIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks

DEGREE (if applicable) NOTE: The Biographical Sketch may not exceed five pages. Follow instructions below.

Structure and Function of Antigen Recognition Molecules

IAS 2013 Towards an HIV Cure Symposium

Can we eradicate HIV?

Inves&gación básica y curación del VIH-1

DEGREE (if applicable)

Chapter 35 Active Reading Guide The Immune System

HIV cure: current status and implications for the future

Hepatitis C Virus Disease

EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells

Transcription:

NAME: Soriano-Sarabia, Natalia OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015) BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. era COMMONS USER NAME: natalia_soriano POSITION TITLE: Research Instructor of Medicine (New early-stage investigator, ESI) EDUCATION/TRAINING INSTITUTION AND LOCATION DEGREE Completion Date FIELD OF STUDY University of Alcala de Henares, Madrid, Spain BS 09/2001 Cellular and Molecular Biology University of Seville, Spain MS 07/2004 Biomedicine University of Seville and Virgen del Rocio Hospital, PhD 07/2007 HIV-HCV coinfection Seville. Spain Innate immunity in HIV Virgen del Rocio Hospital, Seville, Spain Postdoctoral 2007-2009 infection Immune functions of γδ Justus Liebig University, Giessen, Germany Postdoctoral 2009-2011 T cells HIV reservoirs and University of North Carolina at Chapel Hill Postdoctoral 2011-2015 latency 1. Personal Statement The goal of the proposed research is to investigate the role of γδ T lymphocytes in HIV latency. I have a broad background in HIV pathogenesis and long interest in γδ T cells, leaving me with the expertise necessary to carry out the proposed work. My doctoral studies encompassed research in the pathogenesis of HIV and hepatitis C virus coinfection, using both cellular and molecular techniques. As an early postdoctoral fellow I conducted research as PI funded by the Spanish Sanitary Research Foundationfocusing on the innate immunity in HIV-infected patients, mentoring in the PhD program and directing the teaching of graduate degree students. Later, I focused in the study of γδt cells as a postdoctoral fellow in Germany, where I earned a postdoctoral fellowship award from the Max Planck Institute and studied the specific requirements for γδ T cell function. Given the wide range of effector functions these cells can exert, I hypothesized that γδ T cells could be targets for HIV infection, and might play a role in HIV persistence. My grant application to analyze the role of γδ T cells in HIV latency was funded by the Carlos III Institutes of Health, Spain (CD10/00438) and I came to Dr. David Margolis laboratory at the University of North Carolina at Chapel Hill to execute this project. Working with his group, my preliminary studies published in PLoS Pathogens show for the first time that γδ T lymphocytes harbor replication-competent HIV and constitute a previously unrecognized reservoir for HIV-1 infection. A funding application with Dr. Margolis was funded via the R56 bridge mechanism, and I have used this to obtain further data and establish independence. In August 2015, I was promoted to Research Instructor of Medicine and I am optimally positioned to continue this research independently as I have the necessary institutional support to conduct and manage this project independently. I will establish the specific role of γδ T cells in HIV latency, and determine whether specific therapeutics are needed to purge this reservoir of persistent infection. 1. Soriano-Sarabia N, Vallejo A, Molina-Pinelo S, Genebat M, Rodríguez M.M, Sánchez-Quijano A, Martínez-Moya M, Vivancos J, Leal M. HIV-HCV coinfection is associated with decreased plasmatic interleukin-7 levels. AIDS 2007; 21:253-255. 2. Pulido I, Leal M, Genebat M, Pacheco YM, Sáez ME, Soriano-Sarabia N. The TLR4 Asp299Gly is a risk factor for active tuberculosis in Caucasian HIV-infected patients. Curr HIV Res 2010; 8:253-258.

3. Soriano-Sarabia N, Sandvold H, Jomaa H, Bein G, Hackstein H. Primary MHC-Class II+ cells are necessary to promote resting Vδ2 cell expansion in response to (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate and isopentenyl pyrophosphate. J Immunol 2012; 189: 5212-5222. 4. Soriano-Sarabia N, Archin NM, Bateson E, Dahl NP, Crooks AM, Kuruk JD, Garrido C, Margolis DM. Peripheral Vγ9Vδ2 T cells are a novel reservoir of latent HIV infection PLoS Pathog 2015; 11(10):e1005201. This work was presented at the Conference on retroviruses and Opportunistic Infections (CROI). Oral presentation, 2013. B. Positions and Honors Positions and Employment 2015- Research Instructor in Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill Honors and awards 2004 Fellowship award, HIV-DART 2004, Montego Bay, Jamaica. Oral presentation 2007 PhD Magna cum laude 2007 Best oral presentation discussion award, European AIDS Society 2007, Madrid, Spain 2010 Research fellowship award Excellence Cluster, Max Planck Institute, Justus-Liebig University of Giessen and Frankfurt University, Germany 2011 Competitive contract for postdoctoral training Sara Borrell, Carlos III Institutes of Health, Ministry of Innovation and Science, Spain 2013 Young investigator award, CROI 2013, Atlanta, GA. Oral presentation Professional Membership 2002-2009 Member of the HIV Spanish Network (Red de Investigación en SIDA, R.I.S) 2007-2009 Member of the Foundation for the Prevention and Investigation of AIDS in Spain (FIPSE) C. Contribution to Science HIV reservoirs and latency HIV infection remains incurable due to the persistence of a viral reservoir integrated within host cellular DNA. This latent infection, unaffected by antiretroviral therapy and hidden from the immune system, constitutes the major barrier to an HIV cure. Efforts to eradicate HIV infection require the description of all cellular reservoirs that might harbor replication-competent virus. My research is focused in defining new potential reservoirs as we explore new approaches to eradicate HIV infection. 1. Barton KM, Burch BD, Soriano-Sarabia N, Margolis DM. Prospects for treatment of latent HIV. Clin Pharmacol Ther 2013; 93: 46-56. 2. Soriano-Sarabia N, Bateson RE, Dahl NP, Crooks AM, Kuruc JD, Margolis DM, Archin NM. The quantitation of replication-competent HIV-1 in populations of resting CD4 + T cells. J Virol 2014; 88: 14070-14077. 3. Archin NM, Sung JA, Garrido C, Soriano-Sarabia N, Margolis DM. Eradicating HIV infection: Seeking to clear a persistent pathogen. Nature Rev Microbiol 2014; 50: 750-764. 4. Soriano-Sarabia N, Archin NM, Bateson E, Dahl NP, Crooks AM, Kuruk JD, Garrido C, Margolis DM. Peripheral Vγ9Vδ2 T cells are a novel reservoir of latent HIV infection (under review). This work was presented at the Conference on retroviruses and Opportunistic Infections (CROI). Oral presentation, 2013. Innate Immunity As a recent postdoctoral fellow I was interested in different aspects of innate immune responses to HIV infection. TLR regulate the function of both innate and adaptive immune responses. We analyzed the specific role of several SNPs on TLR demonstrating that TLR9 1635/AA was associated with disease progression. In addition, I was the PI in a second study focused on analyzing the impact of SNP on HIV-infected patients comorbidities. We showed that the Asp299Gly SNP is a risk factor for active tuberculosis in HIV-infected patients. These studies have implications as novel therapeutic approaches targeting TLRs are being developed. I also focused my interest for the innate arm of the immune system on γδ T cells, that constitute the bridge between the innate and the adaptive immunity and their function is crucial to establish potent adaptive immune responses. These cells have the capacity to greatly expand and respond very rapidly to a given challenge and

this unique property is being exploited in the cancer field. We developed a highly sensitive sorting method to study specific requirements of γδ T cells to be activated and expand. We demonstrated that the antigens recognized by these cells must be presented by accompanying cells, preferentially dendritic cells, over monocytes/macrophages or αβ T cells. We also defined the expression of protease activated receptors in γδ T cells as well as in other cell types including CD8 cells, monocytes /macrophages and NK cells. 5. López ML, Soriano-Sarabia N, Bruges G, Marquez ME, Klaus T, Preissner KT, Schmitz ML, Hackstein H. Expression pattern of protease activated receptors in lymphoid cells. Cell Immunol 2014; 288:47-52. 6. Soriano-Sarabia N, Vallejo A, Ramírez-Lorca R, Rodríguez MM, Salinas A, Pulido I, Sáez ME, Leal M. Influence of the Toll-like receptor 9 1635A/G polymorphism on CD4 count, HIV viral load and clinical progression. J Acquir Immune Defic Syndr 2008; 49:128-135. This work was presented at the European AIDS Conference (EACS). Oral presentation, 2007. 7. Luque J, Lozano JM, García-Jurado G, Soriano-Sarabia N, González R, Vallejo A, Leal M, Peña J. NK-associated regulatory receptors in a structured HAART interruption of HIV-1+ individuals. AIDS Res Hum Retrovir 2008; 24:1037-1042. Antiretroviral therapy interruption strategies During my graduate studies, it was thought that structured treatment interruptions (STI) held potential for the treatment of HIV. Although clinically unsuccessful, voluntary and supervised STI were extremely helpful in understanding virologic and immunologic processes such as viral rebound, and CD4 cell depletion. We confirmed cellular and viral dynamics to be similar to the set point prior to ART introduction, defining also specific groups of patients who were more likely to need ART at a sooner time than others. These studies were extremely helpful to detect elite controllers that were taken off their medications. We also showed functional and mechanistic aspects of the HIV pathogenesis as well as the role of Hepatitis C virus coinfection. 8. González-Serna A, Abad-Fernández M, Soriano-Sarabia N, Leal M, Vallejo A. Alterations of CD8 T cell receptor Vβ chain repertoire are related with immunologic markers in HIV-1-infected patients during treatment interruption and are restored by antiretroviral therapy. J Clin Virol 2013; 58:703-709. 9. Soriano-Sarabia N, Vallejo A, Fernández G, Genebat M, Gutiérrez S, Muñoz-Fernández MA, Leal M. Control of HIV-1 RNA load alter HAART interruption: relationship with CCR5 co-receptor density and proviral DNA load. J Clin Virol 2007; 40:64-67. This work was presented at the HIV-Frontiers in drug development for antiretroviral therapy Conference (DART). Oral presentation, 2004. 10. Molina-Pinelo S, Vivancos J, De Felipe B, Soriano-Sarabia N, Valladares A, de la Rosa R, Vallejo A, Leal M. Thymic volume predicts CD4 T-cell decline in HIV-infected adults under prolonged treatment interruption. J Acquir Immune Defic Syndr 2006; 42:203-206. 11. Soriano-Sarabia N, Abad MA, Vallejo A, Gutiérrez S, Leal M. HCV and HGV coinfection influence over viral and cellular dynamic in HIV-infected patients on HAART interruption. Clin Microb Infect 2006; 12:290-293. Effect of hepatitis C virus coinfection on HIV pathogenesis My thesis work was focused in understanding how HCV had an effect on HIV infection in patients on antiretroviral therapy. I studied several different aspects of the coinfection from phenotype of the immune cells to functional defects such as decreased capacity of coinfected patients to produce IL-7. This was important as repopulation of CD4 cells was impaired in coinfected patients. We also demonstrated that B cell immunity and antigen production capacity was also impaired. 12. De Felipe B, Leal M, Soriano-Sarabia N, Gutiérrez A, López-Cortés L, Molina-Pinelo S, Vallejo A. HCV RNA in peripheral blood subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse. J Viral Hepatitis 2009; 16:21-27. 13. Soriano-Sarabia N, Vallejo A, Molina-Pinelo S, Genebat M, Rodríguez M.M, Sánchez-Quijano A, Martínez-Moya M, Vivancos J, Leal M. HIV-HCV coinfection is associated with decreased plasmatic interleukin-7 levels. AIDS 2007; 21:253-255. 14. Soriano-Sarabia N, Abad MA, Vallejo A, Gutiérrez S, Leal M. HCV and HGV coinfection influence over viral and cellular dynamic in HIV-infected patients on HAART interruption. Clin Microb Infect 2006; 12:290-293. 15. Soriano-Sarabia N, Leal M, Delgado C, Molina-Pinelo S, de Felipe B, Ruiz-Mateos E, Sánchez- Quijano A, Lissen E, Vallejo A. Effect of hepatitis c virus coinfection on humoral immune alterations in naïve HIV-infected adults on HAART: a three year follow-up study. J Clin Immunol 2005; 25:294-300.

This work was presented at the 13 th Diseases. Oral presentation, 2004. International Symposium on HIV and Emerging Infectious Immune reconstitution in HIV-infected patients naïve for antiretroviral therapy I collaborated in a series of works from our group focused on understanding the mechanisms and implications of the thymus in the immune reconstitution. At that time, it had been just discovered that the thymus was a functional organ. Our group demonstrated the importance of a functional thymus in HIV infection and how its measurement was an accurate tool to predict the immune reconstitution in HIV-infected patients who were naïve for antiretroviral therapy. 16. Molina-Pinelo S, Vallejo A, Díaz L, Soriano-Sarabia N, Ferrando-Martínez S, Resino S, Muñoz- Fernández MA, Leal M. Premature immunosenescence in HIV-infected patients on HAART with lowlevel CD4 T cell repopulation. J Antimicrob Chemoth 2009; 64:579-588. 17. Molina-Pinelo S, Leal M, Soriano-Sarabia N, Gutiérrez S, Fernández G, Muñoz-Fernández MA, Lissen E, Vallejo A. Prevalence and factors involved in discordant responses to highly active antiretroviral treatment in a closely followed cohort of treatment-naïve HIV-infected patients. J Clin Virol 2005; 33:110-115. 18. Ruiz-Mateos E, de la Rosa E, Soriano N, Martínez-Moya M, Rubio A, Sánchez-Quijano A, Leal M, Lissen E. Comparison of thymic function related markers to predict early CD4+ T-cell repopulation in adult HIV-infected patients on HAART. Antiviral Therapy, 2003; 8:289-294. 19. Ruiz-Mateos E, de la Rosa R, Martínez-Moya M, Soriano N, Sánchez-Quijano A, Leal M, Lissen E. Endogenous IL-7 triggers thymic rebound in adult HIV infected patients on HAART. AIDS 2003; 17:947-954. Complete List of Published Work in My Bibliography (23 publications and 1 manuscript in review): http://www.ncbi.nlm.nih.gov/pubmed/?term=soriano-sarabia http://www.ncbi.nlm.nih.gov/pubmed/?term=soriano+n.+hiv D. Research Support Ongoing Research Support R56 AI114464-01A1 Margolis (PI) 03/13/15-02/26/16 The Role of Gamma Delta T Cells as Persistent Reservoirs of HIV Infection The goal of this study is to get preliminary data on the role of γδ T cells in HIV latency Role: Senior Postdoctoral Fellow U19 AI096113-01 Margolis (PI) 07/008/11-06/30/16 Martin Delaney Collaboratory to Eradicate HIV-1 Infection. This project funds 17 principal investigators and 4 cores. The Margolis laboratory receives funding for a research project within this collaborative, to study the effect of reagents to perturb latent infection in CD4+ T cells, to study latent infection in CD4+ cell populations, and a supplement to perform a study of the durability of immune response to AGS-004. Completed Research Support CD10/00438, Carlos III Institutes of Health, Spain Soriano-Sarabia (PI) 09/01/11-11/13/13 γδ T cells in HIV latency This was a competitive Postdoctoral Contract (Sara Borrell) to analyze the role of γδ T cells in HIV latency. Role: PI 2010-2011 Collaborative ECCPS project, Germany Hackstein (PI) 01/10/10-05/31/11 Dissecting novel immune-regulatory functions of γδ T cells Institute for Clinical Immunology and Transfusion Medicine and Max-Plank Institute. We analyse specific requirements of Vδ2 cells to expand in vitro. Role: Co-investigator 0241/2005, Spanish Sanitary Research Foundation Leal (PI) 01/31/07-01/30/09 Role of Toll-like receptors in the morbi-mortality associated to HIV infection

The objective of this project was to analyse the influence of common SNP in TLR in HIV disease progression and opportunistic infections. Role: Postdoctoral fellow PI040272, Spanish Sanitary Research Foundation Leal (PI) 2005-2007 Role of the thymus in viral and cellular kinetics in HIV-infected adults alter HAART interruption The goal of this project was to identify the role of the thymus in the immune repopulation and in the HIV rebound. Role: GR G03/173 Spanish AIDS Research Network (RIS) Leal (PI) 2006 Collaboration Projects in Epidemiology, Basic and Clinic Investigation for the year 2006. This was a collaboratory of Spanish scientists to analyse several aspects of the HIV infection on and off therapy. 02/24 Health Service of Andalusia Leal (PI) 2004 Influence of the Hepatitis C virus coinfection on the immune reconstitution HIV-infected patients on HAART. Analysis of the potential role of thymic dysfunction on the lower reconstitution induced by HCV infection. 03/119 Health Service of Andalusia Vallejo (PI) 2003-2005 Effect of Highly Active Antirretroviral Therapy on humoral immune alterations induced by HIV in adult patients. Influence of the Hepatitis C virus coinfection.